{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:26:08Z","timestamp":1762867568625,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T00:00:00Z","timestamp":1539993600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12882-018-1066-3","type":"journal-article","created":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T07:33:21Z","timestamp":1540020801000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0762-0942","authenticated-orcid":false,"given":"Francesco","family":"Fontana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Alfano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Leonelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Cerami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Ligabue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelia","family":"Spinella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Citriniti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo Umberto","family":"Manzini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clodoveo","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianni","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,20]]},"reference":[{"issue":"12","key":"1066_CR1","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1093\/ndt\/gfv381","volume":"31","author":"Luis F. Quintana","year":"2015","unstructured":"Quintana LF, Jayne D. Sustained remission in lupus nephritis: still a hard road ahead. Nephrol Dial Transplant. 2015:gfv381. \n                    https:\/\/doi.org\/10.1093\/ndt\/gfv381\n                    \n                  .","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"1066_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/rheumatology\/kev311","volume":"55","author":"JG Hanly","year":"2016","unstructured":"Hanly JG, O\u2019Keeffe AG, Su L, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford). 2016;55(2):252\u201362. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kev311\n                    \n                  .","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"1066_CR3","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1681\/ASN.2016040415","volume":"27","author":"S. V. Parikh","year":"2016","unstructured":"Parikh SV, Rovin BH. Current and emerging therapies for lupus nephritis. J Am Soc Nephrol. 2016:1\u201311. \n                    https:\/\/doi.org\/10.1681\/ASN.2016040415\n                    \n                  .","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"1066_CR4","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/ndt\/gfw288","volume":"31","author":"A Kronbichler","year":"2016","unstructured":"Kronbichler A, Neumann I, Mayer G. Moderator\u2019s view: the use of calcineurin inhibitors in the treatment of lupus nephritis. Nephrol Dial Transplant. 2016;31(10):1572\u20136. \n                    https:\/\/doi.org\/10.1093\/ndt\/gfw288\n                    \n                  .","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1066_CR5","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/ndt\/gfs285","volume":"28","author":"M Weidenbusch","year":"2013","unstructured":"Weidenbusch M, R\u00f6mmele C, Schr\u00f6ttle A, Anders HJ. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant. 2013;28(1):106\u201311. \n                    https:\/\/doi.org\/10.1093\/ndt\/gfs285\n                    \n                  .","journal-title":"Nephrol Dial Transplant"},{"key":"1066_CR6","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1056\/NEJMoa031855","volume":"350","author":"G Contreras","year":"2004","unstructured":"Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350:971\u201380. \n                    https:\/\/doi.org\/10.1056\/NEJMoa031855\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"12","key":"1066_CR7","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1177\/0961203317691371","volume":"26","author":"C Sj\u00f6wall","year":"2017","unstructured":"Sj\u00f6wall C, Hjorth M, Eriksson P. Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases. Lupus. 2017;26(12):1333\u20138. \n                    https:\/\/doi.org\/10.1177\/0961203317691371\n                    \n                  .","journal-title":"Lupus"},{"issue":"9767","key":"1066_CR8","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra SV, Guzm\u00e1n RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721\u201331. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(10)61354-2\n                    \n                  .","journal-title":"Lancet"},{"issue":"12","key":"1066_CR9","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1001\/jamasurg.2014.1086.Feasibility","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918\u201330. \n                    https:\/\/doi.org\/10.1001\/jamasurg.2014.1086.Feasibility\n                    \n                  .","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1066_CR10","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3109\/03009742.2014.887769","volume":"43","author":"C Sj\u00f6wall","year":"2014","unstructured":"Sj\u00f6wall C, C\u00f6ster L. Belimumab may not prevent lupus nephritis in serologically active patients with ongoing non-renal disease activity. Scand J Rheumatol. 2014;43(5):428\u201330. \n                    https:\/\/doi.org\/10.3109\/03009742.2014.887769\n                    \n                  .","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"1066_CR11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.autrev.2017.01.010","volume":"16","author":"S Sciascia","year":"2017","unstructured":"Sciascia S, Radin M, Yazdany J, et al. Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus\u00a0: a systematic review. Autoimmun Rev. 2017;16(3):287\u201393. \n                    https:\/\/doi.org\/10.1016\/j.autrev.2017.01.010\n                    \n                  .","journal-title":"Autoimmun Rev"},{"issue":"2","key":"1066_CR12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1523-1755.2004.00443.x","volume":"65","author":"JJ Weening","year":"2004","unstructured":"Weening JJ, D\u2019Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65(2):521\u201330. \n                    https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00443.x\n                    \n                  .","journal-title":"Kidney Int"},{"issue":"1","key":"1066_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.7","volume":"2","author":"JA Kellum","year":"2012","unstructured":"Kellum JA, Lameire N, Aspelin P, et al. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1\u2013138. \n                    https:\/\/doi.org\/10.1038\/kisup.2012.7\n                    \n                  .","journal-title":"Kidney Int Suppl"},{"key":"1066_CR14","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1056\/NEJM199401273300403","volume":"299","author":"JV Donadio Jr","year":"1978","unstructured":"Donadio JV Jr, Holley KE, Ferguson RH, Ilstrup DM. Treatment of Diffuse Proliferative Lupus Nephritis with Prednisone and Combined Prednisone and Cyclophosphamide. N Engl J Med. 1978;299:1151\u20135. \n                    https:\/\/doi.org\/10.1056\/NEJM199401273300403\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"4","key":"1066_CR15","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/acr.22173","volume":"66","author":"M Yurkovich","year":"2014","unstructured":"Yurkovich M, Vostretsova K, Chen W, Avi\u00f1a-Zubieta JA. Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res (Hoboken). 2014;66(4):608\u201316. \n                    https:\/\/doi.org\/10.1002\/acr.22173\n                    \n                  .","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"1066_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11926-016-0571-2","volume":"18","author":"CE Fors Nieves","year":"2016","unstructured":"Fors Nieves CE, Izmirly PM. Mortality in systemic lupus erythematosus: an updated review. Curr Rheumatol Rep. 2016;18(4):1\u20137. \n                    https:\/\/doi.org\/10.1007\/s11926-016-0571-2\n                    \n                  .","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"1066_CR17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.semarthrit.2014.06.001","volume":"44","author":"LR Wang","year":"2014","unstructured":"Wang LR, Barber CE, Johnson AS, Barnabe C. Invasive fungal disease in systemic lupus erythematosus: a systematic review of disease characteristics, risk factors, and prognosis. Semin Arthritis Rheum. 2014;44(3):325\u201330. \n                    https:\/\/doi.org\/10.1016\/j.semarthrit.2014.06.001\n                    \n                  .","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"1066_CR18","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1038\/emi.2016.93","volume":"5","author":"W Fang","year":"2016","unstructured":"Fang W, Chen M, Liu J, et al. Cryptococcal meningitis in systemic lupus erythematosus patients: pooled analysis and systematic review. Emerg Microbes Infect. 2016;5(9):e95. \n                    https:\/\/doi.org\/10.1038\/emi.2016.93\n                    \n                  .","journal-title":"Emerg Microbes Infect"},{"issue":"1","key":"1066_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1177\/0961203312465781","volume":"22","author":"MA Dooley","year":"2013","unstructured":"Dooley MA, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus. 2013;22(1):63\u201372. \n                    https:\/\/doi.org\/10.1177\/0961203312465781\n                    \n                  .","journal-title":"Lupus"},{"issue":"6","key":"1066_CR20","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s10067-015-3153-1","volume":"35","author":"MA De Scheerder","year":"2016","unstructured":"De Scheerder MA, Boey O, Mahieu E, Vanuytsel J, Bogaert AM. Case report: successful treatment of membranous lupus nephritis with belimumab in an African female immigrant. Clin Rheumatol. 2016;35(6):1649\u201353. \n                    https:\/\/doi.org\/10.1007\/s10067-015-3153-1\n                    \n                  .","journal-title":"Clin Rheumatol"},{"issue":"2","key":"1066_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jbspin.2016.01.008","volume":"84","author":"Federico Simonetta","year":"2017","unstructured":"Simonetta F, Allali D, Roux-Lombard P, Chizzolini C. Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab. Jt Bone Spine. 2016:1\u20132. \n                    https:\/\/doi.org\/10.1016\/j.jbspin.2016.01.008\n                    \n                  .","journal-title":"Joint Bone Spine"},{"key":"1066_CR22","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1177\/0961203313504145","volume":"22","author":"E FlieBer","year":"2013","unstructured":"FlieBer E, Korsten P, Koziolek M, et al. Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with Belimumab in a 19-year-old woman. Lupus. 2013;22:1523\u20135. \n                    https:\/\/doi.org\/10.1177\/0961203313504145\n                    \n                  .","journal-title":"Lupus"},{"key":"1066_CR23","unstructured":"Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis. retrieved from \n                    https:\/\/clinicaltrials.gov\n                    \n                  \/ Identification number: NCT01639339. \n                    https:\/\/clinicaltrials.gov\/show\/NCT01639339\n                    \n                  ."}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-1066-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-018-1066-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-1066-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T19:17:23Z","timestamp":1571512643000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-018-1066-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,20]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1066"],"URL":"https:\/\/doi.org\/10.1186\/s12882-018-1066-3","relation":{},"ISSN":["1471-2369"],"issn-type":[{"type":"electronic","value":"1471-2369"}],"subject":[],"published":{"date-parts":[[2018,10,20]]},"assertion":[{"value":"30 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We present a case report, which is a retrospective critical analysis on clinical and laboratory charts of a single patient. The Ethical Committee of the University Hospital of Modena does not require specific evaluation for Case Reports, based on the Operative Procedures of the above mentioned Ethical Committee (12th review, March 28th 2017), which have been transmitted to me via email by the Responsible of the Technical-Scientific Secretary of the Ethical Committee of the University Hospital of Modena. For consent to participate see: consent for publication.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient, who is 17\u00a0years old, was informed about the publication of data and gave her consent; the patient\u2019s mother gave informed consent on the publication of data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no financial or non-financial competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"276"}}